Oncology Clinical Trials Market To Reach $58.9 Billion By 2033

Oncology Clinical Trials Market Growth & Trends

The global oncology clinical trials market size is estimated to reach USD 58.9 billion by 2033, expanding at a CAGR of 7.9% from 2026 to 2033, according to a new report by Grand View Research, Inc. The number of people living with cancer is predicted to rise as lung cancer is the largest cause of cancer-related deaths worldwide, with an estimated 1.8 million people diagnosed and around 60,000 new cases of renal cell carcinoma diagnosed in the U.S. each year. Furthermore, it reflects an increasing prevalence of cancer and an increasing demand for efficient cancer treatment.

The federal government plays a huge role in funding and organizing clinical research in oncology. NCI funds nearly half of all cancer trials in the U.S., and there’s a growing number of studies in phase II, leading to market growth. Moreover, according to the Medicines Healthcare Products Regulatory Agency (MHRA), between 2018 and 2022, the application for phase II and phase III trials increased by 5.5%. IQVIA announced a relationship with Cancer Researchers in September 2019 to enhance the use of real-world data and expand clinical research in oncology.

 Request a free sample copy or view report summary: Oncology Clinical Trials Market Report

Oncology Clinical Trials Market Report Highlights

• Based on phase type, the phase III segment dominated the oncology clinical trials market, accounting for the largest revenue share of 54.3% in 2025. Phase III segment includes the high share of phase III trials, which is attributed to the fact that phase III trials are the most expensive but involve many subjects. Long-term safety studies are conducted for registration and post-marketing commitments in phase III trials

• Based on study design, the interventional studies segment accounted for the largest share of the oncology clinical trials industry in 2025. The driving factors for interventional study design in the oncology clinical trials sector primarily revolve around these conditions' unique challenges

• North America dominated the market with a revenue share of 50.7% in 2025 owing to the well-established pharmaceutical and drug trials regulations in the region. The Asia Pacific oncology clinical trials industry is expanding rapidly due to the presence of untapped opportunities in the emerging economies of China and India

Oncology Clinical Trials Market Report Segmentation

Grand View Research has segmented the global oncology clinical trials market based on phase type, study design, indication, and region:

Oncology Clinical Trials Phase Type Outlook (Revenue, USD Million, 2021 - 2033)

• Phase I

• Phase II

• Phase III

• Phase IV

Oncology Clinical Trials Study Design Outlook (Revenue, USD Million, 2021 - 2033)

• Interventional Studies

• Observational Studies

• Expanded Access Studies

Oncology Clinical Trials Indication Outlook (Revenue, USD Million, 2021 - 2033)

• Lung Cancer

• Breast Cancer

• Colorectal Cancer

• Leukemia

• Prostate Cancer

• Other Cancers

Oncology Clinical Trials Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • UAE

  • Saudi Arabia

  • Kuwait

  • Qatar

  • Oman

List of Key Players in Oncology Clinical Trials Market

• Astrazeneca

• Merck & Co., Inc.

• IQVIA

• Gilead Sciences Inc.

• F. Hoffmann-La Roche Ltd.

• Parexel International Corporation

• Charles River Laboratories

• Syneos Health

• Medpace

• Labcorp Drug Development

• ICON plc

• Thermo Fisher Scientific (PPD)

• WuXi AppTec